Ivosidenib

Langerhans Cell Histiocytosis

National Cancer Institute (NCI)Small moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

22 Active assets in the Langerhans Cell Histiocytosis cohort.

Asset / Sponsor	Phase	Rating
Melphalan M.D. Anderson Cancer Center	Phase 2	B
Palbociclib National Cancer Institute (NCI)	Phase 2	B
Olaparib National Cancer Institute (NCI)	Phase 2	B
Tazemetostat National Cancer Institute (NCI)	Phase 2	B
Rituximab M.D. Anderson Cancer Center	Phase 2	B

View all 27 →

Same molecule, other indications

Ivosidenib is also rated in:

acute myeloid leukemia with multilineage dysplasiaActive

BB

Indicative · Phase 3

66 / 100

myeloproliferative neoplasmActive

B

Indicative · Phase 2

62 / 100

acute myeloid leukemiaActive

B

Indicative · Phase 3

61 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.